Description
Otonomy, Inc. is a clinical-stage biopharmaceutical company. The Company focused on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear. The Company’s lead product candidate, AuriPro, is a sustained-exposure antibiotic for which it has completed two identical Phase III clinical trials in 532 pediatric patients with middle ear effusion, or fluid, at the time of tympanostomy tube placement (TTP), surgery. Its second product candidate, OTO-104, is a sustained-exposure steroid that is in a Phase 2b clinical trial for patients with Meniere’s disease. The Company has global commercialization rights to its product candidates. The Company has developed a formulation technology that provides sustained drug exposure in the middle or inner ear from a single local administration. Its technology utilizes a thermosensitive polymer, which transitions from a liquid to a gel at body temperature.
Address
5626 Oberlin Dr Ste 100
SAN DIEGO, CA 92121-1705
United States
SAN DIEGO, CA 92121-1705
United States
Website
www.otonomy.comKey stats and ratios
| Q2 (Jun '14) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -79.02% | -85.67% |
| Return on average equity | - | - |
| Employees | 37 |
No comments:
Post a Comment